Evidence map›Paper›PMID 38755503›Full record

ArticleAmerican journal of clinical dermatology2024

Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.

Nicole Cherepacha, Frances St George-Hyslop, Bindiya Chugani, Yousef Alabdeen, Luis F Sanchez-Espino, Quenby Mahood, Cathryn Sibbald, Ruud H J Verstegen

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Real-World Data on Severe Cutaneous Adverse Reactions to Drugs.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicole CherepachaTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-4639-6920
Frances St George-HyslopTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Bindiya ChuganiDivision of Clinical Pharmacology and Toxicology, Department of Paediatrics, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada.
Yousef AlabdeenDivision of Immunology and Allergy, Department of Paediatrics, University of Toronto, Toronto, ON, Canada.
Luis F Sanchez-EspinoDivision of Dermatology, Department of Paediatrics, Stollery Children's Hospital, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0001-5136-2851
Quenby MahoodHospital Library, The Hospital for Sick Children, Toronto, ON, Canada.
Cathryn SibbaldDepartment of Paediatrics, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-9288-1121
Ruud H J VerstegenDivision of Clinical Pharmacology and Toxicology, Department of Paediatrics, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada. ruud.verstegen@sickkids.ca.ORCID http://orcid.org/0000-0001-6638-8405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug reaction with eosinophilia and systemic symptoms (DReSS) is known to cause mortality and long-term sequelae in the pediatric population, however there are no established clinical practice guidelines for the management of pediatric DReSS. We conducted a scoping review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to summarize the currently available data on treatment, mortality, and long-term sequelae of DReSS in children (aged 0-18 years). Data from 644 individuals revealed that various treatment strategies are being used in the management of pediatric DReSS, and strategies were often used in combination. The diversity in treatment approaches cannot be solely attributed to age or disease severity and reflects the lack of evidence-based management guidelines for DReSS. Children are also at risk of developing autoimmune sequelae following DReSS, most commonly thyroid disease and type 1 diabetes mellitus. We found that the eventual development of autoimmune disease was more often associated with DReSS caused by antibiotics, especially minocycline and sulfamethoxazole, in comparison with individuals who did not develop sequelae. In this study, we identify strengths and weaknesses in the currently available literature and highlight that future prospective studies with structured and long-term follow-up of children with DReSS are needed to better understand potential risk factors for mortality and development of sequelae after DReSS.

Indexed as

Drug Hypersensitivity SyndromeAdolescentAnti-Bacterial AgentsAutoimmune DiseasesChildChild, PreschoolHumansInfantRisk FactorsSeverity of Illness IndexTreatment OutcomeAnti-Bacterial Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.